| Keywords: |
protein expression; unclassified drug; clinical trial; advanced cancer; cancer risk; follow up; antineoplastic agent; colorectal cancer; cell proliferation; proteins; animals; tumor localization; apoptosis; tumor volume; tumor markers, biological; membrane proteins; skin cancer; odds ratio; editorial; dna methylation; cancer mortality; risk assessment; carcinogenesis; colorectal neoplasms; gene expression regulation, neoplastic; statistical significance; adenoma; drug mechanism; messenger rna; randomized controlled trials; cpg island; cpg islands; colonoscopy; cyclooxygenase 2; anticarcinogenic agents; cancer cell; colon resection; dietary supplements; diet therapy; alpha tocopherol; selenium; drug blood level; risk reduction; arachidonic acid; dna (cytosine 5) methyltransferase; protein methylation; isoenzymes; adenomatous polyp; meta-analysis; selenomethionine; dinoprostone; docosahexaenoic acid; linoleic acid; aerobic metabolism; fatty acid metabolism; prostaglandin-endoperoxide synthases; glutathione peroxidase; polyunsaturated fatty acid; dietary fiber; selenoprotein; selenium compounds; lipoxygenase; humans; human; priority journal; selenoproteins; 1,4 phenylene bis(methylene)selenocyanate; wheat bran
|
